Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Nov 11, 2022

Keywords

ClinConnect Summary

The Serpentine trial is investigating how certain immune cells in the blood can help doctors choose the best cancer treatment for patients with specific types of advanced cancers, including melanoma, breast cancer, and lung cancer. This study aims to develop a simple test that measures these immune cells, which may play a role in how well patients respond to therapy.

To participate, individuals must be between 18 and 90 years old and have a confirmed diagnosis of one of the eligible cancers. They should be in good enough health to follow the study requirements and be willing to provide a tissue sample from their tumor. Participants can expect regular check-ins and will also take part in surveys about their social and psychological well-being. It’s important to note that those with certain health conditions, like HIV or serious mental health issues, and those who are pregnant or breastfeeding cannot join this trial.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included
• • Will and ability to comply with the protocol
• • Willingness and ability to provide an adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis
• • Age from 18 to 90 years at the time of recruitment
• • ECOG Performance Status \<= 2
• • Understanding and signature of the informed consent
• • Consenting to participate to the socio-economical-psychological survey
• • Exclusion Criteria
• • Known history of HIV infection
• • Serious neurological or psychiatric disorders
• • Pregnancy or lactation
• • Inability or unwillingness of participant to give written informed consent
• • Inability or unwillingness to be regularly followed up at the same center